scholarly journals Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review

2019 ◽  
Vol 13 (3) ◽  
pp. 155798831984785 ◽  
Author(s):  
Ang Zheng ◽  
Lin Zhang ◽  
Ziyao Ji ◽  
Lijuan Fan ◽  
Feng Jin
2020 ◽  
Vol 23 (6) ◽  
pp. 656
Author(s):  
Shuai Hao ◽  
Miao Huang ◽  
Wuguo Tian ◽  
Yi Chen ◽  
Jianjie Zhao ◽  
...  

1994 ◽  
Vol 31 (4) ◽  
pp. 759
Author(s):  
Kyung Joo Park ◽  
Chun Hwan Han ◽  
Jeong Geun Yi ◽  
Joo Hyuk Lee

2019 ◽  
Vol 127 (1) ◽  
pp. e18-e22
Author(s):  
Nathalia de Almeida Freire ◽  
Bruno Augusto Benevenuto de Andrade ◽  
Nathalie Henriques Silva Canedo ◽  
Michelle Agostini ◽  
Mário José Romañach

2018 ◽  
Vol 26 ◽  
pp. 103-105
Author(s):  
Ashim K Ghosh ◽  
MM Arif Hosen ◽  
Julekha Khatun ◽  
Hasnina Akhter ◽  
F Farjana Shimu ◽  
...  

Male breast cancer is rare. It accounts for 0.2% of all cancers and about 1% of all breast cancer. Because of the rarity of the disease and the low index of suspension, diagnosis is delayed in a significant fraction of patients. The objective of this article is to increase the medical community's awareness of the disease in this setting and thus favorably change its natural history by earlier diagnosis. The present study reported the case of a 70 year old man who was diagnosed with an advanced infiltrating ductal carcinoma.TAJ 2013; 26: 103-105


Cases Journal ◽  
2008 ◽  
Vol 1 (1) ◽  
Author(s):  
Guo-Li Gu ◽  
Shi-Lin Wang ◽  
Xue-Ming Wei ◽  
Li Ren ◽  
Fu-Xian Zou

2020 ◽  
pp. 030089162097698
Author(s):  
Emma Zattarin ◽  
Francesca Ligorio ◽  
Federico Nichetti ◽  
Giulia Bianchi ◽  
Giuseppe Capri ◽  
...  

Introduction: Breast cancer in men is less common than in women and treatment recommendations are often derived from clinical trials exclusively involving women. Data on efficacy of CDK 4/6 inhibitors, which are the mainstay of treatment for hormone receptor–positive/HER2-negative advanced breast cancer, are lacking in male patients. Case report: We present a clinical case of prolonged benefit from palbociclib in combination with letrozole and LHRH analogue in a man who had previously been treated with six lines of endocrine therapies and chemotherapy regimens but was still in excellent clinical condition. Conclusions: This clinical case demonstrates that male breast cancer stands out as an endocrine-sensitive disease, which could potentially benefit from CDK 4/6 inhibitors in combination with endocrine agents even in very heavily pretreated settings of disease, underscoring both the importance of an accurate selection of patients for later treatment lines, taking into account disease history and previous treatment responses, and the peculiarity of breast cancer in men, which deserves dedicated clinical trials to tailor future recommendations.


The Breast ◽  
2003 ◽  
Vol 12 (2) ◽  
pp. 156-157 ◽  
Author(s):  
D.J Gordon ◽  
K.H Chin ◽  
P.G Budny ◽  
A.R Taylor

Sign in / Sign up

Export Citation Format

Share Document